This inventor holds 1 USPTO granted patent. Top assignee: Galapagos Nv. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: Piet Wigernick: Innovator in Pharmaceutical Compositions
Introduction
Piet Wigernick is a notable inventor based in Mechelen, Belgium. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of inflammatory disorders. His work focuses on developing innovative solutions that address various medical conditions.
Latest Patents
Wigernick holds a patent for "Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders." This invention discloses salts of a Compound 1 that are useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergies, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and diseases associated with hypersecretion of IL6 or interferons. He has 1 patent to his name.
Career Highlights
Piet Wigernick is associated with Galapagos NV, a company known for its innovative approaches in drug discovery and development. His work at Galapagos has allowed him to contribute to advancements in the pharmaceutical industry.
Collaborations
Wigernick collaborates with various professionals in his field, including his coworker Nicolas Luc Sabourault. Their combined expertise enhances the research and development efforts at Galapagos NV.
Conclusion
Piet Wigernick is a dedicated inventor whose work in pharmaceutical compositions has the potential to significantly impact the treatment of inflammatory disorders. His contributions to the field exemplify the importance of innovation in healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
